Loading patent…
AssigneeThe Research Institute at Nationwide Children' s Hospital
InventorsBryce A. Kerlin, Toshiharu Shinoka, Christopher K. Breuer, James W. Reinhardt, Mackenzie Elizabeth Turner
Estimating the term…
Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, alone or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts (“TEVGs”) in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.
A dosage unit for reducing thrombosis or stenosis of tissue engineered grafts, vascular grafts, stents, patches or valves comprising an effective amount of an inhibitor of platelet aggregation selected from the group consisting of inhibitors of ADP mediated platelet signaling through the P2Y1, P2X1 or P2Y12 receptor on the surface of platelets, angiotensin II receptor blocker (ARB) inhibitors, and angiotensin-converting enzyme (ACE) inhibitors to reduce thrombosis or stenosis of the graft following implantation, angioplasty or anastomosis in the vasculature of an individual in need thereof, wherein the dosage is provided in an amount covering the day prior to the implantation, angioplasty or anastomosis, and for a period thereafter until the endothelial surface of the vasculature disrupted by the implantation, angioplasty or anastomosis is restored.
Tissue engineered grafts, vascular grafts, stents, patches or valves comprising an effective amount of an inhibitor of platelet aggregation selected from the group consisting of inhibitors of ADP mediated platelet signaling through the P2Y1, P2X1 or P2Y12 receptor on the surface of platelets, angiotensin II receptor blocker (ARB) inhibitors, and angiotensin-converting enzyme (ACE) inhibitors to reduce thrombosis or stenosis of the tissue engineered grafts, vascular grafts, stents, patches or valves following implantation, angioplasty or anastomosis in the vasculature of an individual in need thereof, wherein the dosage unit is sufficient to provide an effective amount covering the day prior to the implantation, angioplasty or anastomosis, and for a period thereafter until the endothelial surface of the vasculature disrupted by the implantation, angioplasty or anastomosis is restored.
A method for reducing thrombosis or stenosis of tissue engineered grafts, vascular grafts, stents, patches or valves comprising administering to an individual in need thereof an effective amount of an inhibitor of platelet aggregation selected from the group consisting of inhibitors of ADP mediated platelet signaling through the P2Y1, P2X1 or P2Y12 receptor on the surface of platelets, angiotensin II receptor blocker (ARB) inhibitors, and angiotensin-converting enzyme (ACE) inhibitors to reduce thrombosis or stenosis of the graft following implantation, angioplasty or anastomosis in the vasculature of an individual in need thereof.
Dependencies are inferred from the claim text.